Delivery Order SPE2DB22D2009-SPE2DB25FM1MJ
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,374.36 by the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This firm fixed-price, competitively awarded contract (without set-aside designation) is scheduled for completion by August 13, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $2,343.59 by the Defense Logistics Agency (DLA) for the supply of Tezspire 210 mg/1.91 mL pen injectors. This competitive, firm fixed-price contract carries an ultimate completion date of August 22, 2025, and was executed on August 1, 2025. The contract involves no set-aside designation and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical....
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,374.36 by the Defense Logistics Agency (DLA) on April 24, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. This firm fixed-price delivery order, which carries an ultimate completion date of May 15, 2025, represents a competitive award with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This award is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pens with a ceiling value of $9,374.36. This firm fixed-price delivery order, with an ultimate completion date of October 3, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The award was competitively awarded with no set-aside designation and will be performed at the contractor's...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectables. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion deadline of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is a child contract under AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order valued at $9,374.36 by the Defense Logistics Agency (DLA) on September 3, 2025, with an ultimate completion date of September 24, 2025. The delivery order is for Tezspire 210 mg/1.91 mL pen injectors and will be performed at the company's Conshohocken facility. This award was competitively procured with no set-aside designation and...
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 ml pens. The contract, which carries a firm fixed price structure with no set-aside designation, is scheduled for completion by August 12, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,343.59 by the Defense Logistics Agency on August 22, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This competitively awarded, firm fixed-price contract carries an ultimate completion date of September 15, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award involves no set-aside designation, reflecting the company's competitive standing in federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM1MJDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,343.59 by the Defense Logistics Agency (DLA) on September 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen units. The order is set to be completed by October 6, 2025, and will be fulfilled from the company's corporate office location in Conshohocken, Pennsylvania. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procurement processes. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026. The parent IDC enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Tezspire is a specialty medication used in the treatment of severe eosinophilic asthma, reflecting the breadth of therapeutic domains covered under the company's federal pharmaceutical distribution portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 9/15/25 |